Potential Metabolite Markers for Pancreatic Cancer Identified by Metabolomic Analysis of Induced Cancer-Associated Fibroblasts
Yasuyuki Kida, Research Group Leader, Yuka Akagi, Nobuhito Mori, and others, in collaboration with Professor Tatsuya Oda and Professor Takahiro Miyazaki of the University of Tsukuba, have identified a number of specific metabolites that lead to early detection and staging of pancreatic cancer. In solid cancers such as pancreatic cancer, the reaction field where various cell groups interact = Tumor Microenvironment (TME) is involved in drug resistance and immunosuppression causing aggressive tumor growth and inhibition of cancer treatment, which decide success or failure of cure. However, in the existing research, there was no experimental model considering the interaction between the cancer cells and the cancer stroma (stroma). Therefore, we have constructed an "in vitro co-culture system" that can easily assay the interaction between cancer and stromal cells, and a "stroma-rich CDX mouse model" that reproduces the stromal barrier that is characteristic of clinical pancreatic cancer. (Miyazaki et al. Febs. Open.Bio.2020, Miyazaki et al. Scientific) Reports 2021).
Here, we have performed CE-TOFMS, which is a comprehensive metabolic profiling analysis. The results have clarified the metabolic transformation (metabolic reprogramming) that occurs in cancer stromal cells and were able to identify many more specific metabolites. Unlike cancer cells, cancer stromal cells of refractory solid tumors do not have genomic mutations, so they may have robustness as biomarkers and therapeutic targets. In the future, it is expected that a detailed dynamic analysis of the identified biomarkers will enable the early detection and staging of pancreatic cancer. Details of this achievement were published in Cancers on March 8, 2022.
Publication
- Title: Potential Metabolite Markers for Pancreatic Cancer Identified by Metabolomic Analysis of Induced Cancer-Associated Fibroblasts
- Authors: Yoshihiro Miyazaki , Nobuhito Mori, Yuka Akagi, Tatsuya Oda and Yasuyuki S. Kida
- DOI: 10.3390/cancers14061375